Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660730 | 0.87 | PDE4B (0.45) | PDE4BPDE4DPDE4APDE4CKDM4E | |
| SCHEMBL10102194 | 0.80 | MEN1 (0.39) | MAPK14PDE4BPDE4DGRM1KMT2A | |
| SCHEMBL10102187 | 0.80 | MEN1 (0.39) | MAPK14PDE4BPDE4DGRM1KMT2A | |
| SCHEMBL10102192 | 0.80 | MEN1 (0.39) | MAPK14PDE4BPDE4DGRM1KMT2A | |
| SCHEMBL10102177 | 0.79 | SMYD2 (0.37) | KDM4EKMT2AMEN1 | |
| SCHEMBL659838 | 0.74 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CKMT2A | |
| SCHEMBL10107127 | 0.74 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CKMT2A | |
| SCHEMBL4786846 | 0.74 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CKMT2A | |
| SCHEMBL10101878 | 0.72 | PDE4B (0.47) | PDE4BKDM4EL3MBTL1KMT2ANPC1 | |
| SCHEMBL16506070 | 0.71 | RORC (0.50) | PDE4BPDE4DGRM1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | MAPK14 2615/4885PDE4B 823/4885PDE4D 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.